The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
A double‐blind, randomized, placebo‐controlled, parallel group study of THC/CBD spray in peripheral neuropathic pain treatment
Abstract
Background: Peripheral neuropathic pain (PNP) associated with allodynia poses a significant clinical challenge. The efficacy of Δ 9‐tetrahydrocannabinol/cannabidiol (THC/CBD) oromucosal spray, a novel cannabinoid formulation, was investigated in this 15‐week randomized, double‐blind, placebo‐controlled parallel group study. Methods: In total, 303 patients with PNP associated with allodynia were screened; 128 were randomized to THC/CBD spray and 118 to placebo, in addition to their current analgesic therapy. The co‐primary efficacy endpoints were the 30% responder rate in PNP 0–10 numerical rating scale (NRS) score and the mean change from baseline to the end of treatment in this score. Various key secondary measures of pain and functioning were also investigated. Results: At the 30% responder level, there were statistically significant treatment differences in favour of THC/CBD spray in the full analysis (intention‐to‐treat) dataset [p = 0.034; 95% confidence interval (CI): 1.05–3.70]. There was also a reduction in mean PNP 0–10 NRS scores in both treatment groups that was numerically higher in the THC/CBD spray group, but which failed to reach statistical significance. Secondary measures of sleep quality 0–10 NRS score (p = 0.0072) and S ubject G lobal I mpression of C hange (SGIC) (p = 0.023) also demonstrated statistically significant treatment differences in favour of THC/CBD spray treatment. Conclusions: These findings demonstrate that, in a meaningful proportion of otherwise treatment‐resistant patients, clinically important improvements in pain, sleep quality and SGIC of the severity of their condition are obtained with THC/CBD spray. THC/CBD spray was well tolerated and no new safety concerns were identified.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Although these five studies found improvements in nausea with cannabis use, other studies found nausea to be an adverse event associated with cannabis use among some participants.”
From Clinical Practice Guidelines for Cannabis and Cannabinoid-Based Medicines in the Management of Chronic Pain and Co-Occurring Conditions (2024) · cites this paper as [57]
In the citing paper
“The oromucosal spray Sativex that contains an equal mixture of THC and CBD (approved in Canada and European countries) demonstrated a significant analgesic effect in neuropathic pain (Serpell et al, 2014).”
From The endogenous cannabinoid system: a budding source of targets for treating inflammatory and neuropathic pain (2018) · cites this paper as Serpell et al, 2014
Citations
Cites
EuroQol: a new facility for the measurement of health-related quality of life
(1990) · Health Policy · doi:10.1016/0168-8510(90)90421-9 · Cited by 15,736
Pain assessment: global use of the Brief Pain Inventory.
Cs, C., & Km, R. (1994) · PubMed · Cited by 5,178
Core outcome measures for chronic pain clinical trials: IMMPACT recommendations
Dworkin, R. H., Turk, D. C., Farrar, J. T., Haythornthwaite, J. A., Jensen, M. P., Katz, N. P., Kerns, R. D., Stucki, G., Allen, R. R., Bellamy, N., et al. (2005) · Pain · doi:10.1016/j.pain.2004.09.012 · Cited by 3,732
International Union of Pharmacology. XXVII. Classification of Cannabinoid Receptors
Howlett, A. C., Barth, F., Bonner, T. I., Cabral, G., Casellas, P., Devane, W. A., Felder, C. C., Herkenham, M., Mackie, K., Martin, B. R., et al. (2002) · Pharmacological Reviews · doi:10.1124/pr.54.2.161 · Cited by 2,819
Prevalence of chronic pain with neuropathic characteristics in the general population
Bouhassira, D., Lantéri‐Minet, M., Attal, N., Laurent, B., & Touboul, C. (2007) · Pain · doi:10.1016/j.pain.2007.08.013 · Cited by 1,827
Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects.
Russo, E. B. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01238.x · Cited by 1,535
Gabapentin for the Treatment of Postherpetic Neuralgia A Randomized Controlled Trial
Rowbotham, M. C. (1998) · JAMA · doi:10.1001/jama.280.21.1837 · Cited by 1,418
Torrance, N., Smith, B. H., Bennett, M., & Lee, A. J. (2006) · Journal of Pain · doi:10.1016/j.jpain.2005.11.008 · Cited by 1,001
EFNS guidelines on pharmacological treatment of neuropathic pain
Attal, N., Cruccu, G., Haanpää, M. L., Hansson, P. T., Jensen, T. S., Nurmikko, T. J., Sampaio, C., Sindrup, S. H., & Wiffen, P. J. (2006) · European Journal of Neurology · doi:10.1111/j.1468-1331.2006.01511.x · Cited by 877
Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis
Rog, D. J., Nurmikko, T. J., Friede, T., & Young, C. A. (2005) · Neurology · doi:10.1212/01.wnl.0000176753.45410.8b · Cited by 679
Cited by
Sorted by citations
Cannabinoids for Medical Use: A Systematic Review and Meta-analysis
Whiting, P. F., Wolff, R. F., Deshpande, S., Di Nisio, M., Duffy, S., Hernandez, A. V., Keurentjes, J. C., Lang, S., Misso, K., Ryder, S., et al. (2015) · JAMA · doi:10.1001/jama.2015.6358 · Cited by 2,169
Sleep deficiency and chronic pain: potential underlying mechanisms and clinical implications
Haack, M., Simpson, N. S., Sethna, N. F., Kaur, S., & Mullington, J. M. (2019) · Neuropsychopharmacology · doi:10.1038/s41386-019-0439-z · Cited by 696
Molecular Targets of Cannabidiol in Neurological Disorders
Bih, C. I., Chen, T., Nunn, A. V. W., Bazelot, M., Dallas, M. L., & Whalley, B. J. (2015) · Neurotherapeutics · doi:10.1007/s13311-015-0377-3 · Cited by 602
Cannabis-based medicines for chronic neuropathic pain in adults
Mücke, M., Phillips, T., Radbruch, L., Petzke, F. W., & Häuser, W. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012182.pub2 · Cited by 606
Stockings, E., Campbell, G., Hall, W. D., Nielsen, S., Zagic, D., Rahman, R., Murnion, B., Farrell, M., Weier, M., & Degenhardt, L. (2018) · Pain · doi:10.1097/j.pain.0000000000001293 · Cited by 460
Metadata
- Authors
- Serpell, M., Ratcliffe, S., Hovorka, J., Schofield, M., Taylor, L., Lauder, H., & Ehler, E.
- Affiliations
- Gartnavel General Hospital (GB)
- MAC Clinical Research (United Kingdom) (GB)
- General University Hospital in Prague (CZ)
- West Suffolk Hospital (GB)
- GW Pharmaceuticals (United Kingdom) (GB)
- Nemocnice Pardubického Kraje (CZ)
- Corresponding author
- Serpell, M.
- ORCID
- Venue
- European Journal of Pain
- Publisher
- Wiley
- Published
- 2014-01-13
- Volume
- 18
- Issue
- 7
- Pages
- 999-1012
- ISSN
- 1090-3801 (ISSN-L)
- 1532-2149
- OpenAlex
- W2112026566
- Cited by
- 197
- References
- 41
- Citations by year
- 2026: 8 · 2025: 14 · 2024: 15 · 2023: 12 · 2022: 32 · 2021: 24 · 2020: 25 · 2019: 15 · 2018: 20 · 2017: 10 · 2016: 10 · 2015: 9 · 2014: 3
- FWCI
- 7.78
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- European Journal of Pain (publishedVersion)
- PubMed (publishedVersion)
- ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (submittedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Cannabis and Cannabinoid Research
- Health Sciences › Medicine › Physiology (medical) › Pain Mechanisms and Treatments
- Health Sciences › Medicine › Anesthesiology and Pain Medicine › Pain Management and Treatment
- Keywords
- peripheral neuropathic pain, allodynia, oromucosal spray, cannabinoids, tetrahydrocannabinol, cannabidiol, analgesia, sleep quality, treatment-resistant pain, tolerability
- MeSH terms
- Adult, Aged, Aged, 80 and over, Analgesics, Cannabidiol, Dose-Response Relationship, Drug, Double-Blind Method, Female, Humans, Male, Middle Aged, Neuralgia, Pain Measurement, Peripheral Nervous System Diseases, Dronabinol, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
